JeffreySosmanMD

Professor of Medicine, Vanderbilt University

Dr. Sosman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
675 N Saint Clair St
Ste 21-100
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-1106

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1986 - 1989
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1985 - 1986
University of ChicagoResidency, Pathology-Anatomic and Clinical, 1982 - 1985
University of ChicagoInternship, Internal Medicine, 1981 - 1982
Albert Einstein College of MedicineClass of 1981

PubMed

1 citations
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Georgina V Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D Lao
Journal of Clinical Oncology. 2025-03-10
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.
Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede
Cancer Discovery. 2025-02-24
1 citations
Weight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.
Steven D Tran, Noah J Forrest, Vijeeth Guggilla, Geovanni M Perottino, Jodi L Johnson
Journal of Cachexia, Sarcopenia and Muscle. 2025-02-01

Reversing Resistance to PD-1 Inhibitors with Combination Immunotherapy in Patients with Advanced MelanomaApril 8th, 2022
ECOG-ACRIN Cancer Research Group Melanoma Research Team Led by Michael Atkins, MD, Receives the 2023 Paper of the Year Distinction from the Journal of Clinical OncologyJanuary 19th, 2024